Author

N. Thielens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Organism:non-human primate· 1

Frequent Co-Authors

D. Fenel· 2 shared F. Fieschi· 2 shared G. Schoehn· 2 shared I. Bally· 2 shared M. Thepaut· 2 shared A. Amen· 1 shared A. Bernardi· 1 shared A. Ersayin· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. Fenel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Rationally designed Gla-domainless FXa as TFPI bait in hemophilia

A. Thomas, M.-C. Dagher, A. Ersayin, L. Seyve, M. Castellan, C. Moreau, L. Choisnard, N. Thielens, R. Marlu, B. Polack

The paper designs and tests GD-FXa variants to enhance TFPI binding and coagulation restoration in hemophilia.

bioRxiv · Aug 3, 2022 · PreprintBioengineering

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection

G. Sulbaran, P. Maisonnasse, A. Amen, D. Guilligay, N. Bosquet, J. A. Burger, M. Poniman, M. Buisson, S. D. Dylon, T. Naninck, J. Lemaitre, W. Gros, A.-S. Gallouet, R. Marlin, C. Bouillier, , W. Weissenhorn

This study develops a synthetic SARS-CoV-2 S glycoprotein virus-like particle vaccine that protects macaques from infection through strong antibody and T cell responses.

bioRxiv · Jul 26, 2021Immunology

DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

M. Thepaut, J. Luczkowiak, C. Vives, N. Labiod, I. Bally, F. Lasala, Y. Grimoire, D. Fenel, S. Sattin, N. Thielens, G. Schoehn, A. Bernardi, R. Delgado, F. Fieschi

The paper shows DC/L-SIGN receptors on antigen-presenting cells enhance SARS-CoV-2 trans-infection, which can be blocked by a glycomimetic compound.

bioRxiv · Aug 9, 2020Immunology